AZD 1390

Drug Profile

AZD 1390

Alternative Names: [11C]-AZD1390; AZD1390; Radiolabeled AZD-1390

Latest Information Update: 11 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics
  • Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 19 Feb 2018 AstraZeneca completes a phase-I clinical trials in Cancer (In volunteers) in Sweden (IV) (NCT03215381)
  • 13 Feb 2018 AstraZeneca plans a phase I trial for Glioblastoma and Brain metastases (Combination therapy, Recurrent, Metastatic disease) in USA and United Kingdom in February 2018 (NCT03423628)
  • 30 Oct 2017 Preclinical data in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top